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ABSTRACT
Objective: This paper aims to provide estimates of
future diabetes prevalence in the West Bank, occupied
Palestinian territory (oPt), and to compare five future
policy scenarios for diabetes prevention.
Design: We created and refined a mathematical
Markov model that integrates population, obesity and
smoking trends to estimate future diabetes prevalence.
Model parameters were derived from the literature.
Diabetes incidence was estimated using DISMOD
software. We developed the model for the Palestinian
population based on data available for the period
2000–2010, and validated the model by comparing
predicted diabetes prevalence to subsequent actual
observed diabetes prevalence rates.
Setting: West Bank oPt.
Results: Palestinian diabetes mellitus prevalence
estimated by the model (for adults aged 25 or more)
was 9.7% in 2000, increasing to 15.3% by 2010.
Prevalence in men increased from 9.1% to 16.9% and
in women from 10.2% to 13.6%. Comparisons of the
model results with the observed prevalence in the
Palestinian Family Health Survey showed a close fit.
The model forecasts were 20.8% for 2020 and 23.4%
for 2030. A 2.8% reduction in diabetes prevalence
could be achieved if obesity trends start to decline by
5% in a 5-year period. If obesity prevalence was
reduced by 35% in 10 years, as suggested by the
WHO, diabetes prevalence might be decreased by 20%.
Conclusions: The model estimates an increase in the
prevalence of diabetes which poses a large challenge
to the health system. However, if bold but reasonable
action is taken, effective interventions could reduce
diabetes prevalence and hence the number of patients
with diabetes.
INTRODUCTION
The International Diabetes Federation (IDF)
suggested that there will be approximately 365
million people with diabetes worldwide in
2011. The MENA (Middle East and North
Africa) region will have the highest prevalence
of diabetes (12.5%) and the second largest
proportional increase in the number of
people with diabetes (85 million).1 However,
this predicted increase was mainly based on
demographic changes and the assumption
that urbanisation is a satisfactory proxy for risk
factors such as obesity, smoking and physical
activity.2
In Palestine, a few epidemiological studies
have focused on non-communicable diseases
including diabetes.3 Most studies were cross-
sectional in nature and provided estimates of
the current prevalence for diabetes and obesity.
However, the estimates of future prevalence
which are urgently needed for proper planning
are not available. Furthermore, the estimates
reported by the IDF and the Global Burden of
Disease study are broad and do not apply specif-
ically to the Palestinian context.1 2 Thus, this
paper aims to provide estimates of future dia-
betes prevalence in the West Bank, occupied
Palestinian territory (oPt), and offer a model-
ling platform for policy decision-making.
METHODS
The model integrates information on popu-
lation, obesity and smoking trends at a given
point of time to estimate diabetes prevalence
in the future using a Markov model. The
Strength and limitations in this study
▪ The model may be appropriate for most low-
income and middle-income countries because it
is simple, does not require sophisticated statis-
tical software nor huge amounts of specific data.
▪ Not all relevant risk factors, such as physical
inactivity, were included in the current model.
Body mass index was used as a measure of
obesity and finally the limited data available to esti-
mate obesity trends for the Palestinian population.
▪ The model can provide estimates for future dia-
betes prevalence which can inform policy using
different intervention scenarios that can target
the specific risk factors.
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model is implemented in MS Excel and can accommo-
date different diabetes deﬁnitions.
We assume that the population can be divided into
several pools: diabetes mellitus, obese, smoker and
‘healthy’ (eg, non-obese, non-smokers and people
without diabetes). A proportion of the population in
each pool moves through pathways to other states.
Population demographic trends are used to inform the
relative size of the ‘starting states’, and transition probabil-
ities are used to estimate the proportion of persons
moving from the starting states to the diabetes and death
states. There are two ‘absorbing states’: diabetes mellitus
(DM)-related death and non-DM-related deaths. In this
way, mortality competing risks are modelled. Potential
overlaps between the healthy, obese and smoking groups
are managed by calculating the conditional probabilities
of membership.
Data needed
The model requires data by 10-year age and gender bands,
starting at 25, ending 75+. Data needed for the initial year
include population size and age distribution, diabetes
prevalence, obesity prevalence, smoking prevalence and
total mortality. Data needed for subsequent years for fore-
casting purposes include population projections, obesity
and smoking trends. Data needed for incidence calcula-
tion include diabetes prevalence, total mortality and case-
fatality. The sources of data used for trend and validation
are listed in table 1. The Palestinian Demographic and
Health Surveys and Ministry of Health Information Centre
were the main sources of data used. The use of these sec-
ondary data was not needed.
Diabetes incidence and speciﬁc mortality were estimated
using the methods developed by Barendregt et al.4 The
methods for diabetes incidence and speciﬁc mortality are
described in the technical appendix. Diabetes incidence,
case-fatality and mortality stratiﬁed by age and sex were
calculated using DISMOD programme based on three
inputs with the assumption that these parameters are con-
stant over time. However, this was taken into account when
calculating the incidence parameter using trends in
DISMOD: ﬁrst diabetes prevalence for the year 2004
obtained from the Palestinian Demographic Health
Survey, diabetes mellitus remission rate which was assumed
0 and diabetes mellitus relative risk (RR) for mortality
which was estimated as proposed by Barendregt et al,4 and
based on the usual RR for mortality. The formula is
RRADJ ¼ RRpRR þ 1 p
Model validation
Model validation is an important aspect of any model-
ling exercise, frequently overlooked.
We developed a model for the West Bank, oPt, over
the period 2000–2020. During that period, subsequent
surveys were conducted in DHS 2004, PFHS 2006, PFHS
2010, Stepwise Survey 2010 and we compared the model
outputs with the observed prevalence estimates.
Sensitivity analysis
We used the analysis of the extremes method (Briggs),
consisting of running the model with all parameters set
to a minimum and maximum realistic values. This is a
very conservative approach, but allows a more transpar-
ent understanding of the weight of each parameter
regarding model outcomes.
Table 1 Population and prevalence of diabetes, obesity
and smoking prevalence for the starting year 2000
2000 Population
Diabetes
prevalence
Obesity
prevalence
Smoking
prevalence
Men (n=336 965)
25–34 138 888 0.0133 0.159 0.594
35–44 92 050 0.0871 0.195 0.561
45–54 46 207 0.1516 0.353 0.525
55–64 28 582 0.2451 0.324 0.422
65–74 19 508 0.2467 0.298 0.331
75+ 11 730 0.1774 0.268 0.331
Women (n=343 260)
25–34 133 095 0.0052 0.213 0.041
35–44 86 979 0.0386 0.401 0.071
45–54 47 457 0.1522 0.564 0.064
55–64 36 124 0.2833 0.602 0.054
65–74 25 670 0.3294 0.432 0.033
75+ 13 935 0.3696 0.354 0.033
‘What if’ policy questions Reference
Given a 2010 baseline: What will be
the impact of a 5% relative reduction
in obesity prevalence by 2015 on
diabetes burden in the West Bank?
Ministry of Health,
Turkey5
What will be the impact of a 5%
relative reduction in obesity
prevalence by 2020 on diabetes
burden in the West Bank?
Assumption
What will be the impact of a 10%
relative reduction in obesity
prevalence by 2020 on diabetes
burden in the West Bank?
Assumption
What will be the impact of halting the
rise in obesity prevalence (15%) by
2020 on diabetes burden in the West
Bank?
WHO6
What will be the impact of 35%
relative reduction in obesity
prevalence by 2020 (baseline 2010)
on diabetes burden in the West
Bank?
WHO-EMRO
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Policy scenarios
Since there are no current targets for adult obesity at the
national level or for the West Bank, and since obesity is
increasing and is predicted to continue to increase, we
used a Mediterranean country, Turkey targets (scenario 1),
WHO targets (scenario 4) and WHO regional targets
(scenario 5). Further we proposed two targets which
might be feasible (scenario 2) and ideal (scenario 3).
These targets are set for population-based prevention.
RESULTS
Population characteristics at starting point
The prevalence of diabetes among the Palestinian popu-
lation aged 25 and above, living in the West Bank in the
year 2000 was 9.1% for men and 10.2% for women. The
risk factors included in the study were obesity and
smoking (table 2). Obesity is a common risk factor
among the Palestinian population with 22.1% preva-
lence among men and 37.2% among women. Smoking
prevalence was very high among men (53.7%) but very
low among women (5.2%).
Risk factor trends 2000–2030
The changes in obesity and smoking prevalence were
assumed to be linear with various degrees between men
and women and within different age groups. Obesity
prevalence was higher among women compared with men
at 2000 with the highest prevalence observed for the ages
45–54 years and 55–64 years. The prevalence reached
plateau at the age of 55–64 years and 65–74 years for
women and 65–74 years for men. Obesity prevalence
increased in men and women while smoking prevalence
decreased in the period 2000–2030. The decrease in
smoking prevalence varied between the age groups with a
faster decrease among the older age groups.
Obesity prevalence has increased from 22.1% in men
and 37.2% in women in 2000 to 29.1% in men and 39.6%
women in 2010. Smoking trends decreased over 10 years
period. Among men, smoking decreased from 53.7% in
2000 to 51.3% in 2004 and 49.4% in 2010. Among women,
smoking prevalence almost halved between 2000 and
2010.
Diabetes incidence and total mortality
Diabetes incidence was estimated using DISMOD based
on diabetes prevalence, total mortality, case-fatality and
remission rate. The estimated incidence for the year 2004
ranged between 0.002 for those aged 25–34 years to 0.041
and 0.026 for men and women aged 55–64 years and
0.026 for men and 0.011 for women older than 65 years.
Model diabetes prevalence estimates
Palestinian diabetes prevalence estimated by the model (for
those aged 25 or more) was 9.7% in 2000 (95% CI 7.9% to
11.6%), increasing to 15.3% (95% CI 12.3% to 17.6%) by
2010 (ﬁgure 1). Diabetes prevalence is predicted to
increase rapidly between 2010 and 2020 and then the
increase starts to slow down. Prevalence in men increased
from 9.1% (95% CI 7.3% to 11.0%) to 16.9% (95% CI
14.6% to 19.4%) and in women from 10.2% (95% CI 8.4%
to 12.3%) to 13.6% (95% CI 11.3% to 15.8%).
Model validation
Comparisons of the model estimates with the observed
prevalence in the Palestinian Family Health Survey
showed a good ﬁt. The observed prevalence was 10.6
versus 11.4% predicted in 2004, 11.8 versus 12.6% in
2006 and 13.8 versus 15.3% predicted using Stepwise
survey results.
Diabetes prevalence projections
The forecasts were 20.6% (95% CI 18.5% to 23.7%) for
2020 and 21.5% (95% CI 20.7% to 25.8%) for 2030.The
estimated number of patients with diabetes is expected
thus to reach 215 000 in 2015, 289 000 in 2020 and
444 000 in 2030.
Policy scenarios
If trends in obesity start to decline by 5% starting in
2015, a reduction in diabetes prevalence of 8.3% could
be achieved in 15 years (2030). If obesity declined by
10% in 10 years as a realistic target, a 5.3% reduction in
diabetes prevalence of 11.1% might be expected. A
more ambitious scenario assuming a 15% reduction in
10 years to achieve the WHO target might result in a
11.1%. However, achieving the EMRO-WHO target of a
35% obesity reduction in 10 years could result in 20.2%
reduction in diabetes prevalence (table 2).
DISCUSSION
This paper provides, for the ﬁrst time, Palestinian-speciﬁc
future estimates for diabetes prevalence rather than just
reporting point prevalence.
The predicted prevalence is worryingly high and is
expected to increase by 35% from 2010 to 2020. This is
entirely consistent with reports from the IDF.2 The main
factor fuelling this increase in diabetes prevalence is the
expected continuing increase in obesity prevalence.7 The
starting point for obesity prevalence among women is
relatively high and is higher than in men. However, men
are catching up; their increase overtime is much faster
than in women. Although in some countries obesity
prevalence increases and then reaches plateau, this phe-
nomenon is not observed in the Palestinian population
yet. Hence obesity prevalence forecast was based on the
past trend with the assumption of continuous increase.
The estimates of diabetes prevalence calculated from
the model were comparable with actual diabetes preva-
lence measured in the period 2000–2010. The estimates of
diabetes prevalence reported in this paper are believed to
be more realistic compared with the estimates reported by
the IDF and the Global prevalence of diabetes estimates
which were critiqued for under estimating the prevalence
of diabetes, probably as a result of using only demographic
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Table 2 Prevalence of diabetes and the number of people with diabetes estimated for the period 2000 and 2030
Baseline
5% Obese reduction
in 5 years
WHO target to halt
obesity prevalence
(15% in 10 years)
WHO-EMRO 35% obese
reduction in 10 years
5% Obese reduction
in 10 years
10% Obese
reduction
in 10 years
Year
Estimated
number
Estimated
number Number
Estimated
number Number
Estimated
number Number
Estimated
number Number
Estimated
number Number
2015 215 042 211 219 3823 210 278 4764 206 673 8369 212 176 2866 211 219 3823
Min–Max 148 627 292 814 146 443 286 159 146 443 286 159 146 443 286 159 146 443 146 443 146 443 286 159
2020 289 103 277 317 11 786 273 902 15 201 261 510 27 593 280 866 8236 277 317 11 786
Min–Max 207 052 398 856 198 010 372 107 198 010 372 107 198 010 372 107 198 010 198 010 198 010 372 107
2025 365 597 342 837 22 760 335 582 30 015 310 687 54 910 350 552 15 045 342 837 22 760
Min–Max 272 271 515 599 251 930 456 947 251 930 456 947 251 930 456 947 251 930 251 930 251 930 456 947
2030 444 296 407 308 36 988 394 879 49 416 354 622 89 674 420 837 23 458 407 308 36 988
Min–Max 342 629 641 053 307 266 541 257 307 266 541 257 307 266 541 257 307 266 307 266 307 266 541 257
Estimated
prevalence
Estimated
prevalence
Per centage
of reduction
Estimated
prevalence
Per centage
of reduction
Estimated
prevalence
Per centage
of reduction
Estimated
Prevalence
Per centage
of reduction
Estimated
Prevalence
Per
centage of
reduction
2015 18.4 18.1 1.8 18.0 2.2 17.7 3.9 18.2 1.3 18.1 1.8
Min–Max 15.9 20.9 15.7 20.5 15.7 20.5 15.7% 20.5 15.7 20.5 15.7 20.5
2020 20.6 19.8 4.1 19.6 5.3 18.7 9.5 20.1 2.8 19.8 4.1
Min–Max 18.5 23.7 17.7 22.1 17.7 22.1 17.7 22.1 17.7 22.1 17.7 22.1
2025 21.6 20.2 6.2 19.8 8.2 18.3 15.0 20.7 4.1 20.2 6.2
Min–Max 20.1 25.3 18.6 22.5 18.6 22.5 18.6 22.5 18.6 22.5 18.6 22.5
2030 21.5 19.7 8.3 19.1 11.1 17.1 20.2 20.3 5.3 19.7 8.3
Min–Max 20.7 25.8 18.5 21.8 18.5 21.8 2.2 18.5 21.8 18.5 21.8 18.5 21.8
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trends and urbanisation as a proxy for diabetes future inci-
dence.1 2 8 By contrast, our model used country-speciﬁc
trends for diabetes risk factors including obesity and
smoking in addition to the demographic trends, whereas
the Global Burden of Disease (GBD) used urbanisation as
a crude proxy measure for obesity and physical inactivity.2
The estimates of the model and observed diabetes preva-
lence reported in national surveys were comparable.
We suggest that this model may be appropriate for most
low-income and middle-income countries because it is
simple, does not require sophisticated statistical software
nor huge amounts of speciﬁc data. Furthermore, the model
can provide estimates for future diabetes prevalence, which
can inform policy using different intervention scenarios
that can target the speciﬁc risk factors included in the
model. Several estimates and projections for global or
national diabetes prevalence studies are available.
This newly developed model has some limitations. First,
models are simpliﬁcations of reality, and not all relevant
risk factors, such as physical inactivity, were included in the
current model. Reliable physical activity level measure-
ments are difﬁcult to obtain in most low-income and
middle-income countries. However, the independent con-
tribution of physical inactivity to diabetes incidence is low,
suggesting that the impact of policies increasing physical
activity levels in any case is likely to be modest. Second,
BMI is an imperfect measure of obesity, visceral obesity
(WHR) would be preferable, but its availability might not
be as widespread as height and weight measurements.
Third, limited data were available to estimate obesity trends
for the Palestinian population. Having data on obesity for
more than two points in time would improve the estimates
for obesity trends. The model also assumes a constant inci-
dence rate and case-fatality rates for the projections. These
assumptions make the model estimates more conservative,
as both will tend to underestimate the size of the preva-
lence pool. Despite these limitations, the model predictive
ability, as compared with observed, independent estimates
of diabetes prevalence seems to be good.
Policy scenarios and their importance
The paper discusses ﬁve population-based intervention
policy options and assesses their impact on future diabetes
prevalence. Since obesity prevalence is increasing and is
predicted to continue to increase, we selected population-
based interventions targeting obesity. The Palestinians have a
national strategy for preventing the non-communicable dis-
eases. However, this strategy did not set a target for obesity
reduction, hence we used WHO, global and regional targets
(EMRO), plus two additional targets, one feasible and one
ideal. The ambitious targets set by the WHO (a 35%
decrease in obesity) would achieve the highest reduction in
diabetes prevalence, but might not be feasible. Setting a
lower target initially followed by a higher target for longer
term might be more realistic. The implementation of the
proposed intervention needs to be investigated thoroughly.
Public health implications
The people in Palestine and the Middle East face an
increasing prevalence of diabetes. Immediate action is
needed to halt this public health disaster. Diabetes can be
prevented mainly by policy interventions focusing on
obesity reduction. A reduction in calorie intake was rein-
forced by increased physical activity.9–11 The American
Heart Association Council on Epidemiology and
Prevention provided an ecological framework for obesity
prevention that emphasised the importance of the social,
environmental and political context and their powerful
inﬂuence on the behaviour of families and individuals.12
Finally, this model has provided reasonably close esti-
mates of diabetes prevalence for oPt over the 2000–2010
period, compared with values observed in contemporary
independent surveys in the same population. The model
also estimates a worrying increase in the future preva-
lence of diabetes and this will cause huge economic and
healthcare problems.
However, if bold action is now taken, a substantial reduc-
tion in the diabetes prevalence and consequently the
number of patients with diabetes could still be achieved.
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